The company’s Indian subsidiary signs its first full-suite customer partnership in the region with HDFC ERGO Mumbai, Aug. 09, 2023 (GLOBE NEWSWIRE) — Duck Creek Technologies India LLP, a subsidiary of Duck Creek Technologies, today announced a historical milestone with its expansion into the Indian general insurance market. Duck Creek

Thomas Hogan Seasoned Technology Leader to Partner with CEO Yossi Carmil to Further Company Growth and Strategic Priorities TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 08, 2023 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors,

ABU DHABI, Émirats arabes unis, 04 août 2023 (GLOBE NEWSWIRE) — L’Université d’intelligence artificielle Mohamed bin Zayed (MBZUAI) a ouvert deux nouveaux départements et lancé quatre programmes d’études supérieures dans les domaines de la robotique et de l’informatique, afin de répondre à la demande mondiale croissante dans ces secteurs, qui

ABU DHABI, Emirados Árabes Unidos, Aug. 04, 2023 (GLOBE NEWSWIRE) — A Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) estabeleceu dois novos departamentos e quatro programas de pós-graduação associados dedicados à robótica e à ciência da computação, satisfazendo a crescente procura global por estas disciplinas, sendo esperado que atinjam,

تلبية للطلب المتزايد على هذه التخصصات على مستوى العالم أبوظبي، الإمارات العربية المتحدة، 3 أغسطس 2023: أطلقت جامعة محمد بن زايد للذكاء الاصطناعي قسمين جديدين يشملان مجالي علم الروبوتات وعلوم الحاسوب، وذلك تلبية للطلب العالمي المتزايد على هذين التخصصين، إذ من المتوقع أن يصل الطلب إلى 225 مليار دولار[i] في

ABU DHABI, United Arab Emirates, Aug. 03, 2023 (GLOBE NEWSWIRE) — Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) has established two new departments and four associated graduate programs dedicated to robotics and computer science, catering to the surging global demand for these disciplines, which is expected to hit USD

L’étude a montré que l’obéxélimab produisait une amélioration clinique rapide, forte et soutenue, y compris une rémission clinique complète, chez la plupart des patients atteints de ML-IgG4 active Les résultats soutiennent la poursuite du développement de l’obéxélimab pour le traitement de la ML-IgG4 et potentiellement d’autres maladies auto-immunes à médiation

Estudo revelou que o obexelimabe produziu melhora clínica rápida, forte e sustentada, incluindo remissão clínica completa, na maioria dos pacientes com IgG4-RD ativa Os resultados apoiam o desenvolvimento contínuo do obexelimabe para o tratamento de IgG4-RD e potencialmente outras condições autoimunes mediadas por células B WALTHAM, Mass., Aug. 02, 2023